Biological and Environmental Research Ontology

Last uploaded: December 23, 2022
Id http://purl.obolibrary.org/obo/NCIT_C62496
http://purl.obolibrary.org/obo/NCIT_C62496
Preferred Name

Tesevatinib
Definitions
An orally bioavailable small-molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Tesevatinib binds to and inhibits several tyrosine receptor kinases that play major roles in tumor cell proliferation and tumor vascularization, including epidermal growth factor receptor (EGFR; ERBB1), epidermal growth factor receptor 2 (HER2; ERBB2), vascular endothelial growth factor receptor (VEGFR), and ephrin B4 (EphB4). This may result in the inhibition of tumor growth and angiogenesis, and tumor regression.
Type http://www.w3.org/2002/07/owl#Class

All Properties

definition

An orally bioavailable small-molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Tesevatinib binds to and inhibits several tyrosine receptor kinases that play major roles in tumor cell proliferation and tumor vascularization, including epidermal growth factor receptor (EGFR; ERBB1), epidermal growth factor receptor 2 (HER2; ERBB2), vascular endothelial growth factor receptor (VEGFR), and ephrin B4 (EphB4). This may result in the inhibition of tumor growth and angiogenesis, and tumor regression.
prefLabel
Tesevatinib
label
Tesevatinib
PDQ_Closed_Trial_Search_ID
386183
code
C62496
Has_Target
prefixIRI
NCIT:C62496
in_subset
Display_Name
Tesevatinib
Preferred_Name
Tesevatinib
FDA_UNII_Code
F6XM2TN5A1
Contributing_Source
CTRP
FDA
Maps_To
Tesevatinib
CAS_Registry
781613-23-8
NCI_Drug_Dictionary_ID
386183
Legacy Concept Name
XL647
PubMedID_Primary_Reference
22011666
type
Is_Value_For_GDC_Property
subClassOf
PDQ_Open_Trial_Search_ID
386183
Semantic_Type
Pharmacologic Substance
UMLS_CUI
C1541356
Add comment
Add proposal
Delete Subject Author Type Created
No notes to display